New FDA guidance on electronic records and signatures

Area of Science:

• Regulatory Science
• Information Technology in Healthcare
• Pharmaceutical Compliance

Background:

• The U.S. Food and Drug Administration (FDA) is actively developing and releasing guidance documents concerning electronic records and electronic signatures.
• Compliance with these evolving regulations is critical for the pharmaceutical and medical device industries.

Purpose of the Study:

• To inform stakeholders about recently published FDA guidance documents.
• To emphasize the importance of industry engagement and feedback on these regulatory documents.

Main Methods:

• Review of two specific FDA guidance documents: one on validation requirements for electronic records and signatures, and another providing a glossary of terms.
• Analysis of the implications of these guidance documents for regulated industries.

Main Results:

• Two key FDA guidance documents have been recently published.
• These documents address validation requirements and provide definitions for electronic records and signatures.

Conclusions:

• Industry participation through comments is crucial for shaping FDA's final guidance on electronic records and signatures.
• Staying informed about and complying with FDA's electronic records and signatures requirements is essential for regulatory adherence.